CASE REPORT Treatment of intestinal Behçet’s syndrome with chimeric tumour necrosis factor á antibody
نویسنده
چکیده
Few patients with Behçet’s syndrome have gastrointestinal ulceration. Such patients are diYcult to treat and have a higher mortality. Faced with refractory symptoms in two patients with intestinal Behçet’s, we used the tumour necrosis factor á (TNF-á) monoclonal antibody infliximab to induce remission. Both women (one aged 27 years, the other 30 years) presented with orogenital ulceration, pustular rash, abdominal pain, bloody diarrhoea due to colonic ulceration, weight loss, and synovitis. One had thrombophlebitis, digital vasculitis, perianal fistula, and paracolic abscess; the other had conjunctivitis and an ulcer in the natal cleft. Treatment with prednisolone, methyl prednisolone, and thalidomide in one and prednisolone, colchicine, and cyclosporin in the other was ineVective. After full discussion, infliximab (3 mg/kg, dose reduced because of recent sepsis in one, and 5 mg/kg in the other) was administered. Within 10 days the ulcers healed, with resolution of bloody diarrhoea and all extraintestinal manifestations. A second infusion of infliximab was necessary eight weeks later in one case, followed by sustained (>15 months) remission on low dose thalidomide. Remission was initially sustained for 12 months in the other but thalidomide had to be stopped due to intolerance, and a good response to retreatment lasted only 12 weeks without immunosuppression, before a third infusion. The cause of Behçet’s syndrome is unknown but peripheral blood CD45 ãä T cells in Behçet’s produce >50-fold more TNF-á than controls when stimulated with phorbol myristate acetate and anti-CD3. Infliximab could have a role for inducing remission in Behçet’s syndrome. (Gut 2001;49:725–728)
منابع مشابه
Infliximab Induced Leukoencephalopathy and Peripheral Neuropathy: A Case Report and a Review of Literature
Inflammatory bowel disease (IBD) is an idiopathic, chronic condition in which tumor necrosis factor alpha (TNF-α) is thought to play a role [1]. Infliximab (IFX) is a chimeric anti-tumor necrosis factor monoclonal antibody that has a potent anti-inflammatory effect [2]. IFX is currently used as a treatment for severe active cases of IBD in both Crohn’s disease (CD) and ulcerative colitis (UC) t...
متن کاملThe role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor á in the pathogenesis of non-alcoholic steatohepatitis
Background—Small intestinal bacterial overgrowth may contribute to the development of non-alcoholic steatohepatitis, perhaps by increasing intestinal permeability and promoting the absorption of endotoxin or other enteric bacterial products. Aims—To investigate the prevalence of small intestinal bacterial overgrowth, increased intestinal permeability, elevated endotoxin, and tumour necrosis fac...
متن کاملInfliximab and nephrotic syndrome.
Infliximab is a chimeric tumor necrosis factor-alpha (TNF-alpha) monoclonal antibody, which has been used extensively in patients with rheumatoid arthritis and inflammatory bowel disease. It also appears to be effective in other conditions such as psoriasis and ankylosing spondylitis. The major side effect of infliximab is infection. Renal complications are uncommon and not well recognized. Thi...
متن کاملClinical Medicine Insights: Therapeutics
Infliximab is a chimeric monoclonal antibody against anti-tumour necrosis factor alpha that has changed the management of inflammatory bowel diseases. Our review describes its mean clinical and pharmacological features, in order to resume its efficacy in induction and maintenance of clinical remission in both Crohn’s Disease and Ulcerative Colitis. Although its efficacy in induction and mainten...
متن کاملBenefit of anti-TNFalpha treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis.
Historically, AA amyloidosis accounts for almost half of the deaths among patients with juvenile chronic arthritis, mainly due to complications of end stage renal failure. Improved survival has been reported in patients whose underlying inflammatory disorder was brought to remission. Tumour necrosis factor (TNFα) blocking agents have been used successfully in the treatment of inflammatory disor...
متن کامل